FDCR database contains the full text of four related newsletters:
Each newsletter covers U.S. Food and Drug Administration (FDA) regulatory activities, product development, packaging, retailing and advertising, trade association news, and corporate news, including financial operations, mergers and acquisitions, marketing and licensing agreements, and market share. The Rose Sheet also includes descriptions of cosmetics trademarks registered and filed for opposition with the U.S. Patent and Trademark Office.
Sources for all newsletters include new product announcements, market research reports, press releases, sales and earnings reports, U.S. Securities and Exchange Commission (SEC) filings; government and trade association reports; reports from conferences, meetings and conventions; and interviews with industry leaders.
The following alphabetical list provides the two-letter label, the relevant alias, and an example for each FDC Reports database field.
===== ============ Label Name/Example ===== ============ ad Approval Date [Word Indexed] example 1: "970306".ad. example 2: 3 6 97.ad. an Accession Number [Phrase Indexed] example: 0215044038.an. ap Application Number [Word and Phrase Indexed] example: p860022 s35.ap. at Approval Type or Class [Word Indexed] example: supplemental labeling.at. ce Category of Entry [Word Indexed] example: marks registered.ce. co Company Name [Word Indexed] example: bristol myers squibb.co. di Distribution [Word Indexed] example: international.di. ds Description [Word Indexed] example: principle indication.ds. du Date of First Use [Word Indexed] example 1: jan 1994.du. example 2: "1994".du. pd Publication Date [Phrase Indexed] example: 941031.pd. pn Product Name [Word Indexed] example: videx.pn. pt Publication Type [Word Indexed] example: recall.pt. rb Recalled By [Word Indexed] example: manufacturer.rb. rd Recall Date [Word Indexed] example 1: june 2 1993.rd. example 2: "1993".rd. rr Recall Reason [Word Indexed] example: sample lines.rr. so Source [Word Indexed] example: blue sheet.so. tc Trademark Class [Word Indexed] example: "51".tc. td Issued Date [Word Indexed] example 1: 10 25 1994.td. example 2: "1994".td. tf File Date [Word Indexed] example 1: 12 6 93.tf. example 2: "93".tf. ti Title [Word Indexed] example: colorectal cancer.ti. tp Published Date [Word Indexed] example 1: 8 2 94.tp. example 2: "94".tp. tr Trademark Number [Word Indexed] example: 1 859 409.tr. ts Serial Number [Word Indexed] example: 74 465 205.ts. tx Text [Word Indexed] example: allelic loss.tx. up Update Code [Phrase Indexed] example: 9612.up.
The following limits are available from the Limit menu on the Main Search Screen:
Popular Command and Sentence Syntax Limits
Update Code Command Syntax: ..l/1 up=9444 Sentence Syntax: limit 1 to up=9444 FDC Source Publication Command Syntax: ..l/1 so=the blue sheet Sentence Syntax: limit 1 to the blue sheet Publication Type Command Syntax: ..l/1 pt=recall Sentence Syntax: limit 1 to recall
Command Syntax: ..c/fdcr Sentence Syntax: use fdcr
<1>
Accession Number
0059001023.
Update Code
9701
Title
Watson acquisition of Royce would add 19 generic products to; line;
Watson Microzide NDA approved..
Source
The Pink Sheet. 1997 January 6. 59(1). T&G-11.
Publication Type
News (NEW).
Text
(1 of 10)
WATSON ACQUISITION OF ROYCE BRINGS COMPANY 19 MARKETED GENERIC
DRUGS, 11 ANDAs pending at FDA and approximately 15 off-patent drugs
in development. Watson said it was attracted to Royce's pipeline and
its current product line, which has only three products that overlap
with Watson's. The sales and marketing groups at Watson and Royce
will be combined, Watson said Dec. 26.
(2 of 10)
Royce is completing its first profitable year. The
Miami-based company, however, has been caught in the broader downturn
in the generic drug market as competition intensified during the
year.
-sample text truncated-
<2>
Accession Number
0440001009.
Update Code
9701
Title
RESEARCH POLICY: DRUG FIRMS COULD GIVE SUPPLEMENTAL FUNDING TO NIH;
CLINICAL RESEARCH TRAINEES -- DANA-FARBER's NATHAN.
Source
The Blue Sheet. 1997 January 1. 40(1). Page 12.
Publication Type
News (NEW).
Text
(1 of 24)
Funds from the pharmaceutical industry should be solicited by NIH
to provide "new support mechanisms" for young clinical
investigators, Dana-Farber Cancer Institute's David Nathan proposed
at the NIH Advisory Committee to the Director meeting Dec. 12 in
Bethesda.
(2 of 24)
Nathan suggested that NIH enter into a "collaboration with the
pharmaceutical industry, who have an enormous stake in [the] output"
of trainees. He added that "if we can sit down and devise plans
that are appealing to the pharmaceutical industry, jointly, we might
be able to develop a new program with NIH and the pharmaceutical
industry...getting together to get some new money into the system"
(3 of 24)
Nathan, chair of the NIH Director's Panel for Clinical Research,
summarized preliminary recommendations drafted by a panel
subcommittee on training/job opportunities for patient-oriented
research. The subcommittee was chaired by Jean Wilson, University of
Texas Southwestern Medical Center.
(4 of 24)
In all, the panel contains four subcommittees. Three others
focus on NIH funding mechanisms for clinical research, General
Clinical Research Centers (GCRCs), and on funding sources and public
information. An interim report was released at the meeting. A final
version is due in September ("The Blue Sheet" Nov. 6, p. 3).
-sample text truncated-
This database is copyrighted by F-D-C reports, Inc. No part of this database may be duplicated, reproduced or distributed in hard copy, machine-readable or any other form withour prior written permission from F-D-C Reports, Inc. Under no circumstances may this database be reproduced for sale or resale.
Revised 21 March, 1997